The GLP-1 receptor (GLP-1R) agonists liraglutide, exendin-4, and lixisenatide are approved for the treatment of T2DM, which do not affect blood glucose levels in normal glycemic subjects and can be administered to nondiabetic patients (Drucker, 2018). Here, GLP1R is linked to type 2 diabetes mellitus.